Tessera Therapeutics
Tessera Therapeutics is seeking a highly skilled professional to develop and optimize processes for synthesizing and purifying oligonucleotides, supporting their gene writing platform. The role involves working with specialized equipment, troubleshooting, and collaborating across research and manufacturing teams to enable scalable production of oligonucleotide drug substances.
Headquarters
Somerville, Massachusetts, United States
Company Size
201-500 employees
Tessera Therapeutics is an early‑stage life sciences company and a Flagship Pioneering venture developing Gene Writing™, a platform technology that programs engineered proteins to write RNA templates into the genome. The approach is designed to install, replace, or remove DNA sequences—enabling potentially durable, one‑time genetic medicines for inherited and other diseases. Tessera combines proprietary molecular engineering and delivery efforts to build a pipeline of therapeutic programs and partnerships aimed at translating the Gene Writing platform into clinical treatments.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Tessera Therapeutics.
Oligonucleotide Chemistry, Co-Op
Dyne Therapeutics
Research Scientist I/II, Oligonucleotide Chemistry
Diversity Employment
Senior Scientist, Oligonucleotide
CRISPR Therapeutics
Senior/Research Fellow, Oligonucleotide Chemistry [LKCMedicine]
Nanyang Technological University
Senior Scientist (Oligonucleotide Conjugation)
Amgen
Research Associate/Senior Research Associate, Oligonucleotide Chemistry
Korro Bio